Header Logo

Connection

MICHAEL TAYLOR to Xenograft Model Antitumor Assays

Back to Details
This is a "connection" page, showing publications MICHAEL TAYLOR has written about Xenograft Model Antitumor Assays.
MICHAEL TAYLOR
Connection Strength
0.987
Xenograft Model Antitumor Assays
  1. Protocol for preclinical evaluation of locoregionally delivered CAR T?cells in patient-derived xenograft models of brain tumors. STAR Protoc. 2024 06 21; 5(2):103078.
    View in: PubMed
    Score: 0.174
  2. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020 05; 26(5):720-731.
    View in: PubMed
    Score: 0.131
  3. Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy. Cancer Res. 2025 Oct 01; 85(19):3737-3751.
    View in: PubMed
    Score: 0.048
  4. Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression. Nat Commun. 2025 Mar 26; 16(1):2974.
    View in: PubMed
    Score: 0.046
  5. Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma. Genome Med. 2021 06 21; 13(1):103.
    View in: PubMed
    Score: 0.035
  6. Chloride intracellular channel 1 cooperates with potassium channel EAG2 to promote medulloblastoma growth. J Exp Med. 2020 05 04; 217(5).
    View in: PubMed
    Score: 0.033
  7. An autocrine ActivinB mechanism drives TGF?/Activin signaling in Group 3 medulloblastoma. EMBO Mol Med. 2019 08; 11(8):e9830.
    View in: PubMed
    Score: 0.031
  8. ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma. Cancer Res. 2019 08 15; 79(16):4057-4071.
    View in: PubMed
    Score: 0.031
  9. Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Cancer Res. 2019 05 01; 79(9):2111-2123.
    View in: PubMed
    Score: 0.030
  10. BMI1 is a therapeutic target in recurrent medulloblastoma. Oncogene. 2019 03; 38(10):1702-1716.
    View in: PubMed
    Score: 0.029
  11. Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. Nat Commun. 2018 10 08; 9(1):4121.
    View in: PubMed
    Score: 0.029
  12. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. Sci Signal. 2018 09 11; 11(547).
    View in: PubMed
    Score: 0.029
  13. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature. 2018 01 04; 553(7686):101-105.
    View in: PubMed
    Score: 0.028
  14. Disrupting the CD47-SIRPa anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med. 2017 03 15; 9(381).
    View in: PubMed
    Score: 0.026
  15. MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties. BMC Cancer. 2016 Feb 17; 16:115.
    View in: PubMed
    Score: 0.024
  16. Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016 Jan 21; 529(7586):351-7.
    View in: PubMed
    Score: 0.024
  17. MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. Cancer Cell. 2015 Dec 14; 28(6):715-729.
    View in: PubMed
    Score: 0.024
  18. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. Mol Cancer Ther. 2015 Nov; 14(11):2560-8.
    View in: PubMed
    Score: 0.024
  19. EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nat Neurosci. 2015 Sep; 18(9):1236-46.
    View in: PubMed
    Score: 0.024
  20. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. Oncotarget. 2015 Feb 20; 6(5):3359-74.
    View in: PubMed
    Score: 0.023
  21. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. Cancer Res. 2015 Jan 01; 75(1):134-46.
    View in: PubMed
    Score: 0.022
  22. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. Cancer Discov. 2014 Oct; 4(10):1198-213.
    View in: PubMed
    Score: 0.022
  23. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15; 5(9):2355-71.
    View in: PubMed
    Score: 0.022
  24. Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat Genet. 2014 Jan; 46(1):39-44.
    View in: PubMed
    Score: 0.021
  25. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children. Cancer Res. 2013 Nov 15; 73(22):6734-44.
    View in: PubMed
    Score: 0.021
  26. The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis. Am J Pathol. 2012 Nov; 181(5):1762-72.
    View in: PubMed
    Score: 0.019
  27. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One. 2009; 4(3):e4998.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.